Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder
Open Access
- 30 November 2025
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 2043-2056
Abstract
Timely initiation of appropriate major depressive disorder (MDD) therapy is crucial. Medicaid-insured patients with MDD have higher healthcare resource utilization (HRU) and costs than commercially insured patients, making this group essential to study. Claims in the MerativeTM MarketScan® Medicaid Database (2016 to 2022) were used to determine all‑cause and mental health (MH)‑related HRU and healthcare costs of US adults with MDD and ≥ 1 pharmacy claim for cariprazine adjunctive to antidepressant treatment. Outcomes were evaluated in patients initiating cariprazine as their first adjunctive therapy and those initiating cariprazine as a subsequent adjunctive therapy (e.g. after another atypical antipsychotic [AA], non-AA, antidepressant treatment combination). HRU and costs were compared with rate ratios (RRs) and mean cost differences between weighted cariprazine adjunctive therapy cohorts. Among 970 Medicaid beneficiaries meeting inclusion criteria, 392 initiated cariprazine as their first adjunctive therapy and 578 initiated it as a subsequent adjunctive therapy. Patients initiating cariprazine first had significantly lower rates of all‑cause emergency department visits (RR [95% CI] = 0.78 [0.66, 0.94], p < .001) and outpatient (OP) visits (0.80 [0.67, 0.92], p = .012) per patient‑year than those initiating cariprazine subsequently. This translated to lower annual all‑cause medical costs (-$2,101 [-$5,096, -$7], p = .048), driven by lower OP costs (-$2,385, [-$5,251, -$492], p = .016) per patient per year. MH‑related HRU and costs were also significantly lower. Findings from this real‑world study of Medicaid beneficiaries indicate that earlier cariprazine use is associated with potential reduction in the substantial humanistic and economic burden of MDD.Keywords
Funding Information
- AbbVie
This publication has 50 references indexed in Scilit:
- The Humanistic and Economic Burden Associated with Major Depressive Disorder: A Retrospective Cross-Sectional AnalysisAdvances in Therapy, 2024
- The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)Advances in Therapy, 2023
- Mental Health Service Utilization Rates Among Commercially Insured Adults in the US During the First Year of the COVID-19 PandemicJAMA Health Forum, 2023
- Treatment Patterns During Major Depressive Episodes Among Patients with Major Depressive Disorder: A Retrospective Database AnalysisDrugs - Real World Outcomes, 2022
- The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)PharmacoEconomics, 2021
- The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive DisorderPharmacoEconomics, 2021
- Prevalence, treatment patterns, and stay characteristics associated with hospitalizations for major depressive disorderJournal of Affective Disorders, 2019
- Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims DataAdvances in Therapy, 2018
- Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United StatesJAMA Psychiatry, 2018
- Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant TreatmentJAMA, 2017